PD-L1 expression is typically measured through IHC staining of biopsy samples. The results are quantified using a scoring system, often referred to as the Tumor Proportion Score (TPS), which indicates the percentage of tumor cells showing PD-L1 staining. A higher TPS suggests a higher likelihood of response to PD-1/PD-L1 inhibitors.
